alirocumab 150 mg / 1 mL (1 mL INJECTION)
|
$216.9789
|
|
NADAC
|
brand
|
Praluent (1) |
Sanofi US Corporation |
|
alirocumab 150 mg / 1 mL (1 mL INJECTION)
|
$221.6100
|
|
VA Big4
|
|
Praluent (2) |
Regeneron Pharmaceuticals, Inc. |
|
alirocumab 150 mg / 1 mL (1 mL INJECTION)
|
$221.6100
|
|
VA FSS
|
|
Praluent (2) |
Regeneron Pharmaceuticals, Inc. |
|
alirocumab 150 mg / 1 mL (1 mL INJECTION)
|
$224.4650
|
|
VA Big4
|
|
Praluent (2) |
Regeneron Pharmaceuticals, Inc. |
|
alirocumab 150 mg / 1 mL (1 mL INJECTION)
|
$538.7097
|
|
NADAC
|
brand
|
Praluent (1) |
Sanofi-Aventis U.S. LLC |
|
alirocumab 150 mg / 1 mL (1 mL INJECTION)
|
$551.5600
|
|
VA FSS
|
|
Praluent (2) |
Regeneron Pharmaceuticals, Inc. |
|
alirocumab 75 mg / 1 mL (1 mL INJECTION)
|
$217.7073
|
|
NADAC
|
brand
|
Praluent (1) |
Sanofi US Corporation |
|
alirocumab 75 mg / 1 mL (1 mL INJECTION)
|
$221.6100
|
|
VA Big4
|
|
Praluent (2) |
Regeneron Pharmaceuticals, Inc. |
|
alirocumab 75 mg / 1 mL (1 mL INJECTION)
|
$221.6100
|
|
VA FSS
|
|
Praluent (2) |
Regeneron Pharmaceuticals, Inc. |
|
alirocumab 75 mg / 1 mL (1 mL INJECTION)
|
$229.1250
|
|
VA Big4
|
|
Praluent (2) |
Regeneron Pharmaceuticals, Inc. |
|
alirocumab 75 mg / 1 mL (1 mL INJECTION)
|
$540.4710
|
|
NADAC
|
brand
|
Praluent (1) |
Sanofi-Aventis U.S. LLC |
|
alirocumab 75 mg / 1 mL (1 mL INJECTION)
|
$551.5600
|
|
VA FSS
|
|
Praluent (2) |
Regeneron Pharmaceuticals, Inc. |
|